Katherine G. Tarlock, MD

Hematology-Oncology

On staff since September 2014

Academic Title: Assistant Professor

Research Center: Center for Clinical and Translational Research

"The privilege of caring for patients and families during challenging medical diagnoses is what drew me to this field and continues to be the best part of my job. I am dedicated to advancing our understanding of leukemia and being able to offer every child and family the best care."

• Patient Testimonials

  • Arthi Seattle WA 01.13.20

    Dr. Tarlock is the best doctor I have met so far in the 18 years I have lived in Seattle. She is highly knowledgeable, very smart, very responsible, trustworthy and also a very caring person. She gave the best treatment to my son suffering from Leukemia at every stage of his treatment. I will be ever grateful to her for saving his life and giving our family a new beginning.

  • Alison Bellevue, WA 07.26.17

    A wonderful provider! She took care of our 4 year old son when he was very ill on the Hem/Onc floor. We really loved her approach to treating kids. We greatly appreciated her knowledge, care, and compassion.

  Recommend Dr. Katherine G. Tarlock

• Awards and Honors

  Award Name	Award Description	Awarded By	Award Date
  Alberta Corkery Fellowship Travel Award
  American Society of Hematology		Abstract Achievement Award
  Outstanding Pediatric Resident Award		Lucile Packard Children's Hospital
  Outstanding Presentation Award		Seattle Children's Hospital Fellow Research Day
  Alpha Omega Alpha Medical Honor Society
  Pediatric Clerkship Award		Chicago Medical School

• Publications

  Other Publications

  • Tarlock K, Alonzo TA, Gerbing RB, Raimondi SC, Hirsch BA, Sung L, Pollard JA, Aplenc R, Loken MR, Gamis AS, Meshinchi S
    Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group.
    26644412 Clinical cancer research : an official journal of the American Association for Cancer Research, 2016 April 15 : 22(8)1951-7 PMCID:PMC4834220
  • Tarlock K, Alonzo TA, Gerbing RB, Raimondi SC, Hirsch BA, Sung L, Pollard JA, Aplenc R, Loken MR, Gamis AS, Meshinchi S
    Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group.
    26644412 Clinical cancer research : an official journal of the American Association for Cancer Research, 2015 Dec. 7
  • Tarlock K, Chang B, Cooper T, Gross T, Gupta S, Neudorf S, Adlard K, Ho PA, McGoldrick S, Watt T, Templeman T, Sisler I, Garee A, Thomson B, Woolfrey A, Estey E, Meshinchi S, Pollard JA
    Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia.
    25662999 Pediatric blood and cancer, 2015 June : 62(6)1048-54

  ---

  Show More Hide

• Research Funding

  Grant Title	Grantor	Amount	Award Date
  Targeting Novel Pediatric-Specific FLT3 Mutations	Alexs Lemonade Stand Foundation		Feb. 1, 2016 - Jan. 31, 2018
  Validation of Mesothelin as a Therapeutic Target in Childhood AML	Childrens Oncology Group, Integrated Translational Science Center, Hematology		Jan. 1, 2016 - June 1, 2016
  Novel Therapeutic Strategy Identification in Relapsed FLT3/ITD Acute Myeloid Leukemia	Hyundai Hope on Wheels, Young Investigator Award		Dec. 31, 2015 - Dec. 31, 2017
  Pathway Directed Treatment for Refractory AML	Sts Baldricks Foundation, St's Baldrick's Consortium Grant		July 1, 2015 - June 30, 2016
  Identification of Resistance Mechanisms and Novel Therapeutic Strategies in Tyrosine Kinase Inhibitor Resistant FLT3/ITD Acute Myeloid Leukemia	Alexs Lemonade Stand Foundation, ALSF Young Investigator Award		July 1, 2014 - June 30, 2016
  Biology and Prognostic Implications of FLT3 Mutations in AML	National Cancer Institute/National Institutes of Health, R01 CA 114563,		Sept. 20, 2012 - July 31, 2017